Cargando…

Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity

GnRH agonists (GnRHa) are a useful tool for pretreatment before artificial endometrial preparation for frozen-thawed embryo-transfer (FET). Their prolonged administration has been associated with thyroid dysfunction, both hyper and hypothyroidism. The aim of this study is to investigate the impact o...

Descripción completa

Detalles Bibliográficos
Autores principales: Marin, Loris, Ambrosini, Guido, Noventa, Marco, Filippi, Flavia, Ragazzi, Eugenio, Dessole, Francesco, Capobianco, Giampiero, Andrisani, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019438/
https://www.ncbi.nlm.nih.gov/pubmed/35465072
http://dx.doi.org/10.1155/2022/6331657
_version_ 1784689277667377152
author Marin, Loris
Ambrosini, Guido
Noventa, Marco
Filippi, Flavia
Ragazzi, Eugenio
Dessole, Francesco
Capobianco, Giampiero
Andrisani, Alessandra
author_facet Marin, Loris
Ambrosini, Guido
Noventa, Marco
Filippi, Flavia
Ragazzi, Eugenio
Dessole, Francesco
Capobianco, Giampiero
Andrisani, Alessandra
author_sort Marin, Loris
collection PubMed
description GnRH agonists (GnRHa) are a useful tool for pretreatment before artificial endometrial preparation for frozen-thawed embryo-transfer (FET). Their prolonged administration has been associated with thyroid dysfunction, both hyper and hypothyroidism. The aim of this study is to investigate the impact of GnRHa administration on thyroid function in women undergoing artificial endometrial preparation. Seventy-eight euthyroid women undergoing endometrial preparation with hormone replacement for FET were retrospectively reviewed. They were divided into two groups according to pretreatment with GnRHa (group A, 42 women) or with an oral contraceptive (group B, 36 women). Group A was subsequently divided into two subgroups according to thyroid autoimmunity presence. Thyroid function has been evaluated and compared among groups and subgroups. Our results did not show any statistically significant differences in age, body mass index, and basal thyroid stimulating hormone (TSH). Total estradiol dosage, duration of treatment, and endometrial thickness were comparable among groups. When TSH was measured 14 days after embryo transfer, no significant differences between the two groups were reported. Among women of group A, TSH was significantly higher only in women with thyroid autoimmunity. GnRHa seems to be associated with thyroid dysfunction in women with thyroid autoimmunity undergoing hormone replacement therapy for FET.
format Online
Article
Text
id pubmed-9019438
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-90194382022-04-21 Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity Marin, Loris Ambrosini, Guido Noventa, Marco Filippi, Flavia Ragazzi, Eugenio Dessole, Francesco Capobianco, Giampiero Andrisani, Alessandra Int J Endocrinol Research Article GnRH agonists (GnRHa) are a useful tool for pretreatment before artificial endometrial preparation for frozen-thawed embryo-transfer (FET). Their prolonged administration has been associated with thyroid dysfunction, both hyper and hypothyroidism. The aim of this study is to investigate the impact of GnRHa administration on thyroid function in women undergoing artificial endometrial preparation. Seventy-eight euthyroid women undergoing endometrial preparation with hormone replacement for FET were retrospectively reviewed. They were divided into two groups according to pretreatment with GnRHa (group A, 42 women) or with an oral contraceptive (group B, 36 women). Group A was subsequently divided into two subgroups according to thyroid autoimmunity presence. Thyroid function has been evaluated and compared among groups and subgroups. Our results did not show any statistically significant differences in age, body mass index, and basal thyroid stimulating hormone (TSH). Total estradiol dosage, duration of treatment, and endometrial thickness were comparable among groups. When TSH was measured 14 days after embryo transfer, no significant differences between the two groups were reported. Among women of group A, TSH was significantly higher only in women with thyroid autoimmunity. GnRHa seems to be associated with thyroid dysfunction in women with thyroid autoimmunity undergoing hormone replacement therapy for FET. Hindawi 2022-04-12 /pmc/articles/PMC9019438/ /pubmed/35465072 http://dx.doi.org/10.1155/2022/6331657 Text en Copyright © 2022 Loris Marin et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Marin, Loris
Ambrosini, Guido
Noventa, Marco
Filippi, Flavia
Ragazzi, Eugenio
Dessole, Francesco
Capobianco, Giampiero
Andrisani, Alessandra
Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity
title Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity
title_full Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity
title_fullStr Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity
title_full_unstemmed Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity
title_short Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity
title_sort thyroid dysfunction after gonadotropin-releasing hormone agonist administration in women with thyroid autoimmunity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019438/
https://www.ncbi.nlm.nih.gov/pubmed/35465072
http://dx.doi.org/10.1155/2022/6331657
work_keys_str_mv AT marinloris thyroiddysfunctionaftergonadotropinreleasinghormoneagonistadministrationinwomenwiththyroidautoimmunity
AT ambrosiniguido thyroiddysfunctionaftergonadotropinreleasinghormoneagonistadministrationinwomenwiththyroidautoimmunity
AT noventamarco thyroiddysfunctionaftergonadotropinreleasinghormoneagonistadministrationinwomenwiththyroidautoimmunity
AT filippiflavia thyroiddysfunctionaftergonadotropinreleasinghormoneagonistadministrationinwomenwiththyroidautoimmunity
AT ragazzieugenio thyroiddysfunctionaftergonadotropinreleasinghormoneagonistadministrationinwomenwiththyroidautoimmunity
AT dessolefrancesco thyroiddysfunctionaftergonadotropinreleasinghormoneagonistadministrationinwomenwiththyroidautoimmunity
AT capobiancogiampiero thyroiddysfunctionaftergonadotropinreleasinghormoneagonistadministrationinwomenwiththyroidautoimmunity
AT andrisanialessandra thyroiddysfunctionaftergonadotropinreleasinghormoneagonistadministrationinwomenwiththyroidautoimmunity